Harrower A D, Yap P L, Nairn I M, Walton H J, Strong J A, Craig A
Br Med J. 1977 Jul 16;2(6080):156-9. doi: 10.1136/bmj.2.6080.156.
We studied secretion of growth hormone (GH), insulin, and prolactin in eight women with anorexia nervosa and nine women with refractory obesity before and during treatment with bromocriptine, 10 mg/day. In the anorexic patients the raised plasma GH concentrations occurring during an oral glucose tolerance test fell significantly while on bromocriptine treatment, but there was no change in plasma insulin or blood glucose concentrations. In the obese patients, however, plasma GH concentrations remained low during the oral glucose tolerance test, and were not modified by bromocriptine. Blood glucose and plasma insulin concentrations were also unchanged. Plasma GH and plasma 11-hydroxycorticosteroid responses to insulin-induced hypoglycaemia were unaffected. Serum prolactin concentrations which were raised in five anorexic patients and marginally raised in two obese subjects, fell significantly in both groups during treatment. We observed no consistent weight changes in either groups.
我们研究了8名神经性厌食症女性患者和9名难治性肥胖女性患者在使用溴隐亭（每日10毫克）治疗前及治疗期间生长激素（GH）、胰岛素和催乳素的分泌情况。在厌食症患者中，口服葡萄糖耐量试验期间出现的血浆GH浓度升高在使用溴隐亭治疗时显著下降，但血浆胰岛素或血糖浓度没有变化。然而，在肥胖患者中，口服葡萄糖耐量试验期间血浆GH浓度仍然很低，且未被溴隐亭改变。血糖和血浆胰岛素浓度也没有变化。血浆GH和血浆11-羟皮质类固醇对胰岛素诱导的低血糖的反应未受影响。5名厌食症患者血清催乳素浓度升高，2名肥胖受试者略有升高，两组在治疗期间均显著下降。我们在两组中均未观察到一致的体重变化。
